{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-091220","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.840726+00:00","generated_at":"2026-05-31T12:18:00.956020+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cogent Biosciences Q2 2024 net loss $59.0M; cash $389.9M; trial enrollment on track for 2025 readouts","bullets":["Cash, cash equivalents and marketable securities $389.9M as of June 30, 2024; expected to fund operations into 2027.","Net loss $59.0M for Q2 2024, compared to $44.1M in Q2 2023; R&D expenses $54.3M.","Enrollment in SUMMIT, PEAK, APEX registration-directed trials on track; topline results expected from all three in 2025.","Appointed Cole Pinnow as Chief Commercial Officer; initiated IND-enabling studies for CNS-penetrant ErbB2 program.","Plan to initiate Phase 1 trial for FGFR2 inhibitor in H2 2024; IND-enabling studies for PI3Ka program ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-091220","json":"https://secwatch.observer/filing/0000950170-24-091220.json","markdown":"https://secwatch.observer/filing/0000950170-24-091220.md","text":"https://secwatch.observer/filing/0000950170-24-091220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000095017024091220/0000950170-24-091220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000095017024091220/cogt-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:18:00.956020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}